A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Inclusion Criteria:

1. Subjects must voluntarily agree to participate in the trial and sign a writteninformed consent form;

2. Age range: 18-75 years old, both male and female are welcome;

3. Patients with histologically or cytologically confirmed unresectable locallyadvanced or metastatic solid tumors which is relapsed or refractory to standardtreatment, or lack of standard treatment;

4. Have at least one measurable tumor lesion per RECIST v1.1;

5. ECOG performance status of 0-1;

6. Life expectancy ≥ 12 weeks;

7. Adequate bone marrow and organ function.

Exclusion Criteria:

1. Patients with active central nervous system metastases or meningeal metastases;

2. Systemic antitumor therapy was received 4 weeks before the start of the study;

3. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate orhigher pleural effusion or pericardial effusion;

4. Have poorly controlled or severe cardiovascular disease;

5. Subjects with active hepatitis B or active hepatitis C;

6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1per NCI-CTCAE v5.0.